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Summary
Ovarian cancer is typically a disease susceptible to systemic antineoplastic treatment. Systemic antineoplastic therapy 
is indicated in almost all FIGO stages of ovarian cancer. In very early stage, well diﬀ erentiated disease, benefi t gained with 
chemotherapy (CT) is no bigger than the 5-year survival rate per se, 90-98%, therefore CT is not indicated in these stages. In 
all other stages, the systemic antineoplastic therapy is aplicable and desirable. It is based on platinum compounds, cisplatin 
and carboplatin, with addition of paclitaxel. For years, there was no advance in systemic chemotherapy treatment in ovarian 
cancer. The disease is treated as early, advanced and recurrent, and recurrent as platinum sensitive and platinum resistant 
disease, and this is how the drugs are being applied. Platinum basis, along with taxane partner is the basis and standard 
protocol, precisely carboplatinum – paclitaxel. There are also some other active agents, such as pegylated liposomal doxo-
rubicin, topotecan etc. Beside the chemotherapy, a biological therapy holds an important spot in treating (epithelial) ovarian 
cancer. Bevacizumab showed eﬃ  ciency and benefi t in platinum resistant and platinum sensitive recurrent disease, as well 
as in advanced, nonmetastatic and nonrecurrent disease. PARP inhibitor olaparib gained accelerated approval on the basis 
of signifi cantly improved fast overall response rate and duration of response. It is yet to be shown, whether all the benefi ts 
of neoadjuvant approach, dose dense regimen, metronomic chemotherapy and intraperitoneal way of application of CT in 
treating ovarian cancer are being explored. 
KEY WORDS: epithelial ovarian cancer, systemic treatment, carboplatinum, paclitaxel, bevacizumab, olaparib, FIGO stages, 
platinum - sensitive disease, platinum - resistant disease
RAK JAJNIKA – SUSTAVNA TERAPIJA I ULOGA BIOMARKERA
Sažetak
Rak jajnika u načelu je bolest osjetljiva na sustavnu antineoplastičnu terapiju. Sustavno antineoplastično liječenje indi-
cirano je u gotovo svim FIGO stadijima bolesti. U vrlo ranom, dobro diferenciranom raku jajnika, benefi t postignut kemote-
rapijom ne razlikuje se od 5 –godišnje stope preživljenja same po sebi, stoga kemoterapija u ovim stadijima nije indicirana. 
U svim drugim stadijima, sustavna antineoplastična terapija primjenjiva je i poželjna. Temeljena je na derivatima platine, 
cisplatini i karboplatini, uz dodatak paklitaksela. Godinama u sustavnoj terapiji raka jajnika nije bilo napretka. Bolest se li-
ječi kao rani, uznapredovali te rekurentni rak jajnika, a rekurentna bolest kao platina - rezistentna i platina – osjetljiva bolest 
i na taj način se primjenjuju i lijekovi. Platinska baza uz taksanski partner, točnije karboplatina – paklitaksel temelj su i 
standardni protokol liječenja. Također su aktivni i neki drugi agensi, poput pagiliranog liposomalnog doksorubicina, topo-
tekana i sl. Osim kemoterapije, važnu ulogu ima i biološka terapija. Bevacizumab se pokazao učinkovitim i donio benefi t u 
liječenju rekurentnog paltina – rezistentnog, paltina – osjetljivog , kao i u liječenju uznapredovalog, nemetastatskog nereku-
rentnog raka jajnika. PARP inhibitor olaparib dobio je odobrenje ubrzanim postupkom na temelju značajno poboljšane brze 
sveukupne stope odgovora te trajanja odgovora. Ostaje za vidjeti jesu li i koliko iskorištene prepoznate prednosti neoadju-
vantnog pristupa, dose dense režima primjene, metronomičke terapije te intraperitonealnog načina apliciranja terapije. 
KLJUČNE RIJEČI: epitelni karcinom jajnika, sustavno liječenje, karboplatina, paklitaksel, bevacizumab, olaparib, FIGO stadiji, 
platina – osjetljiva bolest, platina – rezistentna bolest
Libri Oncol., Vol. 43 (2015), No 1–3, 67 – 74
68
ARTICLE
Ovarian cancer is the fi fth most common ma-
lignancy and the fourth most common cause of 
death from malignancy in women. Most often suf-
fer older, postmenopausal women, with the tip of 
the incidence of the disease in the eighth decade of 
life. A clear cause of the disease is not known, but 
there are indisputable risk factors that contribute 
to increased risk of disease, such as reproductive 
history (earlier menarche, late menopause, fewer 
pregnancies, a total of longer reproductive age 
and the number of ovulations over a lifetime), 
obesity, family history and ethnicity, as well as 
some of the mutations of somatic and germ cells, 
such as the BRCA genes (1). 
The ovarian cancer is mostly epithelial origin 
and according to World Health Organization it is 
divided into several subtypes. These are serous, 
endometrioid, clear-cell, mucinous, Brenner tran-
sitionary, mixed epitheloid and undiﬀ erentiated 
and unclassifi ed epitheloid ovarian cancer. Non-
epithelial ovarian neoplasms are germ cell and 
stromal tumors, or tumors of sexual trace. Sub-
types of ovarian cancer showed prognostic signifi -
cance (2). A degree of diﬀ erentiation, and tumor 
grade are also signifi cant prognostic factors. There 
are several systems of graduation, none is univer-
sal and adjustment to the subtype of tumor is nec-
essary. The most common among listed epitheli-
oid subtypes of ovarian cancer is serous subtype 
and in over 80% of cases of detected advanced 
ovarian cancer it is about invasive serous carcino-
ma. The disease is heterogeneous and there is a 
general classifi cation by the dual model, into type 
1 and type 2 tumors (3). To the subtypes of a high-
er degree of malignancy, so-called ovarian neo-
plasms type 2, belong extremely aggressive tu-
mors of high grade and degree of aggressiveness. 
Type 1 tumors are indolent neoplasms, with low-
grade and less aggressive nature. Ovarian cancer 
is graded according to FIGO (International Feder-
ation of Gynecology and Obstetrics) classifi cation.
Access to the treatment of ovarian cancer be-
gins by choosing adequate surgical methods of 
treatment. In the early, localized ovarian cancer, 
surgery is undertaken within the meaning and 
purpose of tumor resection and adequate staging 
of the disease. In advanced ovarian cancer surgi-
cal treatment aims at maximum cytoreduction, or 
removal of all visible signs of the disease, as far as 
possible. This proved important in prolonging the 
survival without relapse (PFS), and in prolonga-
tion of overall survival (OS) (4). Surgical treatment 
in recurrent ovarian cancer makes sense, and is as-
sociated with prolongation of survival, only if 
complete resection of the tumor is possible (5).
Ovarian cancer is typically a disease suscep-
tible to systemic antineoplastic treatment. System-
ic antineoplastic therapy is indicated in almost all 
FIGO stages of ovarian cancer. The stages IA and 
IB of well diﬀ erentiated ovarian cancer have high 
fi ve-year survival rate, 90 to 98 %, which does not 
change with the application of adjuvant chemo-
therapy (CT), therefore it is not indicated in these 
stages (6). In stage IA and IB grade 2 observation 
is indicated, or three to six cycles of intravenous 
CT. High risk patients, such as those with stage IB 
and IC disease and grade 2/3, those with any stage 
of disease and grade 3, stage II, as well as the pa-
tients with clear-cell ovarian cancer, recorded a 
clear benefi t from the administration of adjuvant 
chemotherapy in comparison to the observation 
only, the absolute benefi t in the survival rate of 8 
%, compared to those patients treated with CT af-
ter relapse (74 % vs. 82 %) (7, 8).
The boom of a systemic treatment of ovarian 
cancer began with the appearance of cisplatin (C) 
followed by carboplatin (K). All the entry studies 
except one of French authors, showed equal eﬃ  -
ciacy of C and K, along with a bett er toxicity pro-
fi le of K (9-11). The conclusion of this fi rst-genera-
tion platinum derivative studies, submitt ed in 
AOCTG metaanalysis, was inconclusive, but sug-
gested benefi t in survival compared with nonplat-
inum protocols, the benefi t of the combination 
compared to monotherapy with platinum deriva-
tives, and equivalent eﬃ  cacy of C and K, along 
with a much bett er tolerability and toxicity profi le 
of K (9).
The next generation of studies gave rise to 
the monochemotherapy with K as the gold stan-
dard for adjuvant systemic therapy of ovarian 
cancer. Thus, compared to the CAP protocol (cy-
clophosphamide, doxorubicin, cisplatin) mono-
therapy with K was equally eﬀ ective in prolong-
ing the OS (both treatments achieved median sur-
vival of 33 months, with a two - year OS 60% in 
both groups), yet less toxic (12, 13). After the dis-
covery of paclitaxel (P), in the 1980 – ies, and after 
its activity was proven in recurrent ovarian can-
cer, research of its application in the adjuvant che-
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motherapy of ovarian cancer was conducted. 
Thus, the combination of cisplatin and paclitaxel 
(CP) in the treatment of advanced ovarian cancer 
was shown to be superior, compared to combina-
tion of cyclophosphamide and cisplatin, with the 
greater objective response rate (oRR, 59% vs. 45%), 
clinical complete response (CCR, 41% vs. 27%), 
less minimal residual disease (MRD), longer PFS 
(median 15.5 vs. 11.5 months) and OS (median 
35.6 vs. 25.8 months), which has become the stan-
dard choice for the treatment (14,15). The combi-
nation of paclitaxel with carboplatin (PK) was 
equally eﬀ ective, as compared to the combination 
of the CP, in oRR, CCR, PFS and OS, with a sim-
plier administration and a bett er toxicity profi le of 
PK combination. Therefore, this combination be-
comes the new standard in the treatment of ad-
vanced ovarian carcinoma (16, 17). In a study com-
paring a standard CT doublet PK with triplet 
CAP, standard protocol proved equally eﬀ ective 
and, again, less toxic as compared to the triplet, 
and once more the possibility of choosing K mono-
therapy, due to its low toxicity, was proven (13). 
Application of adjuvant CT with PK combination, 
in the optimally operated patients with stage III 
ovarian cancer, showed prolongation of PFS for 
seven months (21 vs. 28 months), and median OS 
for fi ve months (52 vs. 57 months), in comparison 
to former standard protocols, which did not con-
tain P (cisplatin, cyclophosphamide) (14). If surgi-
cal treatment is not optimally carried out, the re-
sults are worse. 
Neoadjuvant systemic antineoplastic therapy 
for now in the treatment of ovarian cancer is not a 
standard approach and is used mainly in the case 
of weaker performance status of the patient, when 
it is impossible to immediately access the surgical 
treatment. Instead, on average, three cycles of 
standard intravenous CT (PK protocol) is admin-
istered preoperatively, followed by surgery (18). 
So, the surgical approach is through interval cyto-
reduction, inbetween the applied chemothera-
py. Compared to standard adjuvant therapy, it 
showed no advantage in PFS nor OS (19). Ongoing 
studies will eventually undoubtedly position the 
possibilities of neoadjuvant treatment in ovarian 
cancer (CHORUS, Kumar, JCOG0602) (20). 
In stage II and III disease, other than intrave-
nous CT, the intraperitoneal chemotherapy (IPK) 
takes into account. This is, in the case of optimal 
debulking, when the tumor mass is less than 1 cm, 
and in the absence of residual disease after surgi-
cal treatment. In these patients, IPK showed ben-
efi t in OS of nearly 66 compared to 49 months, 
with standard intravenous CT (21). IPK comprises 
of applying part of CT, commonly a platinum 
agent, directly into the peritoneal cavity through 
the catheter. Since it is more demanding and more 
toxic, it did not become part of standard clinical 
practice. Nevertheless, IPK in the optimally oper-
ated patients with stage III disease proved to be 
arguably the most eﬀ ective and in these cases is 
still recommended.
In order to achieve maximum eﬃ  ciency in 
the application of P a dose - dense regimen of ther-
apy is also in use. With this approach, there was a 
clear benefi t in PFS and OS after three years of 
follow-up (extension of the OS for 38 months, 100 
vs. 62), and longer follow-up confi rmed the un-
doubted benefi t in patients with residual disease 
greater than 2 cm (22). P means application on a 
weekly basis at a dose of 80 mg / m2, with the use 
of K in the standard way, every three weeks. This 
regimen expressed myelotoxicity, even up to 92% 
of patients (23). In case of prophylactic use of G-
CSF, grade 3 or 4 neutropenia appears in only 35% 
of patients (24). For now, said treatment regimen 
is considered optional, but not standard clinical 
practice.
Despite optimal treatment of surgical tech-
niques and adjuvant systemic therapy, 70% of pa-
tients with ovarian cancer will experience a recur-
rence within three years. In order to prevent re-
currence, a consolidation therapy and maintenance 
therapy were investigated. Consolidation therapy 
was a short-term application of high doses of CT, 
immediately after completion of primary treat-
ment, while maintenance therapy accounted for 
extended administration of monotherapy (25). 
None of these CT approaches has shown benefi t in 
OS. Maintenance therapy by prolonged adminis-
tration of P showed a benefi t in PFS (26), but the 
fi nal results and the possible impact on the OS are 
still pending (27). 
Prognosis and eﬀ ectiveness of second-line 
therapy, or likely response to the second and each 
subsequent line of therapy, mostly depends on the 
period between the last application of CT and re-
ported disease progression. According to the lat-
est consensus, the disease can be divided into 
platinum - refractory ovarian cancer, when the 
progression is recorded during treatment or with-
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in four weeks after the last administration of plat-
inum-based therapy; platinum - resistant disease, 
when the disease progression established within 
six months of the last cycle of the platinum thera-
py; partially platinum - sensitive disease, when 
the progression appears between six and 12 
months from the last cycle of platinum therapy 
and platinum - sensitive ovarian cancer, when the 
disease progresses after more than 12 months 
since the last cycle of therapy based on platinum 
(28). This division is conditional, based on obser-
vational studies and likelihood of assumed an-
swer is not always the same. Platinum - resistant 
and refractory disease have a poor prognosis, with 
expected overall survival of less than 12 months. 
In these patients, treatment is aimed at improving 
the quality of life and relieving symptoms. Possi-
ble therapeutic option in these situations are 
weekly or three - weekly P, docetaxel, topotecan, 
pegylated liposomal doxorubicin (PLD), gem-
citabine, vinorelbine, oral etoposide, and the re-
sponse rate to these drugs in the study was about 
15%, with a median PFS of approximately three to 
four months. Topotecan showed activity similar 
to that of P, when administered to patients with 
relapse after platinum therapy (29), and no diﬀ er-
ence was seen in the comparison with pegylated 
liposomal doxorubicin in this indication (30). Also, 
even in platinum - drug resistant disease, some-
times platinum therapy can still be applied, for 
example, dose dense regimen. Among the men-
tioned therapeutic choice, no drug has proved su-
perior to the others and the selection of the drug in 
these situations is based on the assessment of tox-
icity, the clinical condition of the patient and the 
possibility, or convenience of administration. 
Combination therapy showed no advantage over 
monotherapy, and toxicity is higher. Therefore, it 
is recommended to use sequential monotherapy.
In patients with relapsed disease, established 
after more than six months after the last applica-
tion of platinum therapy, especially after more 
than 12 months, carboplatin doublet PK is the 
treatment of choice, which is the only one that 
showed benefi t in OS in studies (31). In the plati-
num-sensitive disease, a number of diﬀ erent ther-
apeutic combinations can be considered, usually 
containing platinum.
In order to avoid toxic side eﬀ ects, and with 
the eﬀ ect on the tumor growth continuous admin-
istration of low doses of cytotoxic drugs, so called 
metronomic therapy is tested. In the platinum - re-
sistant ovarian cancer low doses of cyclophospha-
mide administered continuously per os demon-
strated benefi t in PFS, without the side eﬀ ects (32). 
Since this actually blocks tumor angiogenesis, the 
benefi t was observed with cyclophosphamide 
metronomic therapy in combination with anti-
VEGF therapy (bevacizumab) in time to progres-
sion, PFS and OS (33).
Although a clearly higher toxicity of standard 
CT protocols was recorded in elderly patients (> 65 
y), in studies involving older patients it was shown 
that a signifi cant portion of them can withstand the 
default of the standard CT and has signifi cant ben-
efi t of it (31, 34, 35) . With individual access, there 
can clearly be distinguished a proportion of older 
patients who will undoubtedly benefi t from the 
standard applied CT doublets (36).
Apart from the above mentioned standard 
CT regimens, systemic therapy of ovarian cancer 
involves a choice of endocrine therapy (ET). It is 
rarely used in epithelial ovarian cancer, and is 
quite common in use in stromal tumors. In pre-
menopausal patients LHRH agonists goserelin 
and leuprolide are in use, and in postmenopausal 
women lowering of estrogen levels is achieved 
with the use of aromatase inhibitors. Tamoxifen is 
in use in advanced epithelial cancer. In patients 
who have previously received cytotoxic treat-
ment, tamoxifen does not induce an objective an-
swer, but high percentage of these women experi-
ence at least short-term objective stabilization of 
disease (37). In the platinum - resistant recurrent 
epithelial ovarian cancer tamoxifen showed the 
median of survival 15 months, median PFS 4 
months, and oRR as the only element of signifi -
cant predictive value for PFS (38). Eﬀ ect in the 
treatment of advanced ovarian cancer resistant to 
fi rst or second line CT is seen also with medroxy-
progesterone acetate (39).
The systemic treatment of ovarian cancer also 
involves biological therapy. Since angiogenesis is 
an important element of the growth of ovarian 
cancer, VEGF inhibitor bevacizumab was shown 
to be eﬀ ective in addition to CT. Bevacizumab is 
approved by the European Medicines Agency, in 
fi rst line treatment, at a dose of 15mg / kg, with PK 
through six three – week cycles, and then to a 
maximum of 15 months of application, or ob-
served disease progression. Precisely, the bevaci-
zumab maintenance therapy during one year, af-
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ter six cycles of three – week CT, signifi cantly re-
duces the risk of progression or death, with good 
tolerability and almost same side eﬀ ects as the 
control group (GOG 218 trial) (40). Nevertheless, 
bevacizumab is not used consistently, and in the 
United States is not even approved in this indica-
tion. Greater benefi t in survival is observed in 
high-risk patients with stage III – IV disease and 
residual disease > 1 cm, but the drug showed ef-
fect also in high-risk patients in the early stages of 
the disease (40, 41). Addition of bevacizumab to 
CT containing K and P is most strongly recom-
mended in patients with advanced disease, poor 
prognostic factors such as stage IV disease or sub-
optimal debulking achieved previously (41). Bev-
acizumab has also been approved in the treatment 
of disease relapse. In the platinum - sensitive ovar-
ian cancer, administered with gemcitabine and 
carboplatin CT, it showed signifi cantly bett er PFS 
(median 12.4 vs. 8.4 months), improvement in the 
overall oRR (78.5 % vs. 57.4 % ), and improvement 
in OS, containing a higher number of discontinua-
tion in treatment and hypertension, as compared 
to the control group (34). Bevacizumab has proven 
eﬀ ective in prolonging PFS and raising the re-
sponse rate (RR) also in patients with platinum - 
resistant relapsed disease, when applied with some 
of the available CT agents in case of resistance to 
platinum compounds and then as maintenance 
therapy until progression. Thus, with topotecan, 
PLD and weekly P it showed signifi cant improve-
ment in PFS, oRR, OS and safety profi le (42).
Pan TK inhibitor and the inhibitor of angio-
genesis pazopanib showed signifi cant prolonga-
tion of PFS compared to placebo, without the me-
dian OS reached, in the maintenance therapy, in 
patients that have not progressed to fi rst-line ther-
apy of advanced ovarian cancer, and with a rela-
tively well tolerability (43). Also, in platinum – re-
sistant disease, administered with paclitaxel, pa-
zopanib prolonged PFS signifi cantly, but with 
high incidence and severity of side eﬀ ects, there-
fore it is not indicated (44).
Important role in treatment is also played by 
PARP (poly - ADP ribose polymerase) inhibitors, 
new drugs that work in a way to prevent tumor 
DNA repair, once it is damaged by other chemo-
therapeutics. PARP inhibitors have shown the 
greatest eﬃ  ciency in BRCA mutant patients with 
recurrent disease (45). The most famous in use is 
the olaparib, which has proven successful in the 
treatment of recurrent platinum - sensitive disease 
in patients with BRCA mutations, as well as in pa-
tients with serous ovarian cancer and high-grade, 
without the mutations, in addition to CT and then 
as maintenance therapy (46). The drug has extend-
ed PFS but not OS, and was approved by acceler-
ated procedure on the basis of signifi cantly im-
proved oRR (34%) and duration of response (me-
dian DOR 7,9 months) (47). It is necessary to 
further study the eﬀ ectiveness of the drug in plati-
num - drug resistant disease.
In the screening, diagnosis and follow-up, 
during and after completion of primary treatment 
of patients with ovarian cancer, it is helpful to 
measure levels of tumor marker CA125. Reliabili-
ty increases linearly with the degree of severity of 
the disease. It is elevated in only 50% of patients 
with early-stage ovarian cancer, and increases up 
to 85% in the advanced stage of the disease (48). 
The absolute value of CA125 measured before ap-
plying the therapy showed prognostic value (49), 
and serum CA125 halfl ife during initial treatment 
is an independent prognostic factor for survival, 
rate of progression and likelihood of achieving 
complete remission (50). In cases where it is un-
clear whether the tumor is of gastrointestinal ori-
gin, or primary ovarian mucinous tumor, levels of 
CEA and CA19-9 are also being measured. During 
treatment, levels of CA125 should be measured 
during each cycle of therapy. The important role 
of CA125 is in evaluating recurrence. Serial mea-
suring the level of CA125 can detect recurrence 
even three to fi ve months before clinical signs of 
the disease (51). According to GCIG criteria, it is 
necessary to measure the serial values of marker, 
as well as at least two measured and confi rmed 
elevated CA125 values, with at least one week in-
terval between measurements (52). Initiation of 
treatment of disease specifi ed by the return value 
of CA125 increase did not show benefi ts in OS, 
compared to a method of waiting until the appear-
ance of clinical symptoms, and quality of life of 
patients in this group were lower, clearly, because 
of earlier and greater total exposure to a chemo-
therapeutic treatment (53).
Ovarian cancer remains an incurable disease 
for many patients. The most controversial area re-
mains the treatment of recurrent disease. After 
many years without news in the systematic treat-
ment with chemotherapy, the last few years fol-
lows the blossoming of biological therapy. The 
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success of biological agents, such as inhibitors of 
angiogenesis was observed in the treatment of 
other solid tumors, and, given the molecular 
mechanisms and signaling pathways underlying 
ovarian cancer, there was an att empt to achieve 
the same in the ovarian cancer. At this point, a sure 
place in systemic therapy of ovarian cancer is po-
sessed by bevacizumab and PARP inhibitors, and 
on the horizon are other biologic agents, likewise 
or modifi ed in activity, and phase III trials, which 
will bring out the necessary evidence for a defi nite 
introduction of the same in everyday clinical prac-
tice. Also, it is yet to exhaust the possibilities of 
various modes of systematic chemotherapy treat-
ment, such as neoadjuvant treatment, metronomic 
therapy, dose - dense regimen of administration 
and intraperitoneal chemotherapy, in which the 
benefi ts were undoubtedly recognized. 
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